397 related articles for article (PubMed ID: 23948943)
1. Cellular prion protein as a therapeutic target in Alzheimer's disease.
Laurén J
J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
[TBL] [Abstract][Full Text] [Related]
2. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
[TBL] [Abstract][Full Text] [Related]
3. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
Aimi T; Suzuki K; Hoshino T; Mizushima T
J Neurochem; 2015 Aug; 134(4):611-7. PubMed ID: 25963375
[TBL] [Abstract][Full Text] [Related]
4. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Aβ interacts with cellular prion protein inducing neuronal membrane damage and synaptotoxicity.
Peters C; Espinoza MP; Gallegos S; Opazo C; Aguayo LG
Neurobiol Aging; 2015 Mar; 36(3):1369-77. PubMed ID: 25599875
[TBL] [Abstract][Full Text] [Related]
6. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.
Decker H; Jürgensen S; Adrover MF; Brito-Moreira J; Bomfim TR; Klein WL; Epstein AL; De Felice FG; Jerusalinsky D; Ferreira ST
J Neurochem; 2010 Dec; 115(6):1520-9. PubMed ID: 20950339
[TBL] [Abstract][Full Text] [Related]
7. The association between prion proteins and Aβ₁₋₄₂ oligomers in cytotoxicity and apoptosis.
Hyeon JW; Kim SY; Park JS; Choi BY; Lee SM; Ju YR; An SS; Kim CK
Biochem Biophys Res Commun; 2012 Jul; 424(2):214-20. PubMed ID: 22743555
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM
Nat Neurosci; 2012 Sep; 15(9):1227-35. PubMed ID: 22820466
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain.
Takahashi RH; Tobiume M; Sato Y; Sata T; Gouras GK; Takahashi H
Neuropathology; 2011 Jun; 31(3):208-14. PubMed ID: 21062360
[TBL] [Abstract][Full Text] [Related]
10. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Um JW; Strittmatter SM
Prion; 2013; 7(1):37-41. PubMed ID: 22987042
[TBL] [Abstract][Full Text] [Related]
12. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
13. Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures.
Bate C; Williams A
Neurobiol Dis; 2018 Mar; 111():48-58. PubMed ID: 29272738
[TBL] [Abstract][Full Text] [Related]
14. Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Folch J; Petrov D; Ettcheto M; Abad S; Sánchez-López E; García ML; Olloquequi J; Beas-Zarate C; Auladell C; Camins A
Neural Plast; 2016; 2016():8501693. PubMed ID: 26881137
[TBL] [Abstract][Full Text] [Related]
15. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance.
Smith LM; Kostylev MA; Lee S; Strittmatter SM
J Biol Chem; 2019 Apr; 294(15):6042-6053. PubMed ID: 30787106
[TBL] [Abstract][Full Text] [Related]
16. The synaptic protein neuroligin-1 interacts with the amyloid β-peptide. Is there a role in Alzheimer's disease?
Dinamarca MC; Weinstein D; Monasterio O; Inestrosa NC
Biochemistry; 2011 Sep; 50(38):8127-37. PubMed ID: 21838267
[TBL] [Abstract][Full Text] [Related]
17. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
Laurén J; Gimbel DA; Nygaard HB; Gilbert JW; Strittmatter SM
Nature; 2009 Feb; 457(7233):1128-32. PubMed ID: 19242475
[TBL] [Abstract][Full Text] [Related]
18. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
[TBL] [Abstract][Full Text] [Related]
19. Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau
Ondrejcak T; Klyubin I; Corbett GT; Fraser G; Hong W; Mably AJ; Gardener M; Hammersley J; Perkinton MS; Billinton A; Walsh DM; Rowan MJ
J Neurosci; 2018 Dec; 38(50):10595-10606. PubMed ID: 30355631
[TBL] [Abstract][Full Text] [Related]
20. Peptide aptamer targeting Aβ-PrP-Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model.
Ali T; Klein AN; Vu A; Arifin MI; Hannaoui S; Gilch S
Cell Mol Life Sci; 2023 May; 80(6):139. PubMed ID: 37149826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
